Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 1997

View Archived Issues

MedImmune: Q3 1997 highlights

Amgen: Q3 1997 highlights

Isis Pharmaceuticals: Q3 1997 highlights

Centocor: Q3 1997 highlights

NeXstar: Q3 1997 highlights

MS&D develops nonpeptide tachykinin antagonists

Anti-HCMV pseudopeptides disclosed by Bayer

Beta3-adrenoceptor agonists reported by Asahi Chemical

Neovascularization inhibitors disclosed by Takeda

Novopharm Biotech cleared for phase I trials of melanoma immunotherapy

Millennium and Monsanto enter genomics alliance

AIT-082 shows promise for spinal cord injury

Novel targets for selectively interfering with chronic or neuropathic pain

RiboGene and Pharmacopeia to discover antiinfective compounds

Vertex's neurophilin program makes progress

NIH awards research grant for development of Cel-Sci's AIDS vaccine

Genome Therapeutics reaches milestone in H. pylori collaboration

Muscarinic receptor antagonists claimed by Pfizer for IBS, Alzheimer's disease

New oxazolidinone antibacterial agents discovered at Zeneca

HMR reports dual H1/NK1 receptor antagonists

Ortho discloses peptide serine protease inhibitors

Univ. Pennsylvania/Sparta issued seventh U.S. patent covering protease inhibitors

Profile of a peptide antidepressant: INN-00835

Mibefradil and amlodipine compared in patients with exercise-induced and silent ischemia

AD-8717: a novel proton pump inhibitor in the pipeline at Dainippon

Niemann-Pick Type C disease-related technology available for licensing from NIH

NIAID researchers report advances in gene therapy for CGD

Renewal of thymopoiesis in mouse model of HIV infection proves feasible

Lifecore reaches patient enrollment milestone in Intergel study

Inflammatory and angiogenic protein-related technology available for licensing

Genetic animal model of psychiatric disorders available for licensing

Medarex launches human antibody business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...